Innovation award recognises STIMULAN Rapid Cure as the only calcium sulfate antibiotic … Continue reading “Biocomposites wins two Queen’s Awards for Enterprise in Innovation and International Trade”
To meet the growing global demand for respiratory active pharmaceutical ingredients (APIs), … Continue reading “Leading inhalation APIs expert Inke to triple production capacity”
AMPLIVANT® adjuvant technology has the potential to increase vaccine immune response 10 … Continue reading “ISA Pharmaceuticals announces the start of clinical trial using its novel AMPLIVANT® technology”
Brighton, United Kingdom – 12 April 2022 – Destiny Pharma plc (AIM: DEST), … Continue reading “Destiny Pharma – Audited results for the year ended 31 December 2021”
Research findings from two studies demonstrate the antimicrobial effectiveness of STIMULAN® and … Continue reading “Biocomposites to present data on STIMULAN® and genex® at ECCMID 2022”
Copenhagen, Denmark, April 11th, 2022 – Adcendo ApS (“Adcendo”), a biotech company … Continue reading “Adcendo – Data Presentation on uPARAP targeting ADCs in Osteosarcoma PDX Models at the 2022 AACR Annual Meeting”
Deal value of up to US$525 million Novo Holdings co-led ReViral Series … Continue reading “Novo Holdings Portfolio Company ReViral to be Acquired by Pfizer”
GENT, BELGIUM, April 5, 2022 – eTheRNA immunotherapies NV (“eTheRNA”), an mRNA … Continue reading “eTheRNA Announces Relocation and Expansion of R&D Facility”
• Findings published in the peer-reviewed journal ACS Chemical Neuroscience demonstrated increased … Continue reading “Asceneuron Publishes Pioneering Preclinical Efficacy Data on its Novel Clinical Molecule ASN90 in Both Alzheimer’s and Parkinson’s Disease Models”
Deployed close to EUR 1.9 billion of equity* Expanded portfolio to 18 … Continue reading “Novo Holdings’ Principal Investments Provides Update on a Record Year”
Bionical Emas, a global Contract Research Organisation (CRO) providing services to the … Continue reading “Bionical Emas: Ian Fraser appointed as Executive Vice President, Clinical Development.”
BioCity, Scotland, 30th March 2022 £1 million grant will support first-in-human clinical … Continue reading “Invizius Awarded Major Biomedical Catalyst Grant to bring Anti-Inflammatory Haemodialysis Treatment to The Clinic”
The funding will accelerate the AI-driven healthcare company’s global market expansion and … Continue reading “Novo Holdings and HealthQuad invest in Qure.ai”
• Started clinical trial with lead candidate RJx-01 for treating sarcopenia • … Continue reading “Rejuvenate Biomed Started a Groundbreaking Clinical Trial and Expands for Future Growth”
NIEL, BELGIUM, March 29, 2022, eTheRNA Manufacturing, a specialist RNA process developer … Continue reading “eTheRNA Manufacturing Announces New LNP Formulation Development and Production Service”
OSLO/LONDON, 28 March 2022: EXACT Therapeutics AS (“EXACT-Tx”, Euronext Growth: EXTX), a clinical … Continue reading “EXACT Therapeutics Announces Appointment of Dr Per Walday as Chief Executive Officer”
Turku, Finland – 28 March 2022: – DelSiTech Ltd, the leading silica drug … Continue reading “DelSiTech Enters into an Exclusive Licensing Agreement with Optifye Therapeutics for the Development of a Controlled Release Ophthalmic Eye Drop Product”
GDT002 shown to have a potent anti-tumor activity across a broad spectrum … Continue reading “Gadeta to Present Data on Tumor-Specific Cell Therapies at Leading Scientific Conferences”
Copenhagen, Denmark – Novo Holdings realised Total Income and Returns of DKK 37 … Continue reading “Novo Holdings reports Total Income and Returns of DKK 37 billion (€5 billion) in 2021, representing a 29% increase over 2020”
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2022 Optimum Strategic Communications All rights reserved.
The Spice Building
8 Devonshire Square
London
EC2M 4PL
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com
